Sino Biopharmaceutical Limited clinical trials

Also known as CTTQ, Sino Biopharm.

The registry lists 470 studies whose lead sponsor is Sino Biopharmaceutical Limited or one of 14 companies grouped under it. 164 are recruiting or about to start. Per ClinicalTrials.gov, last updated Oct 22, 2026.

Studies

Recruiting first, then most recently updated. Showing 50 of 470. Browse all 470 →

• Clinical Trial of TQB3126 for Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy in Breast Cancer SubjectsRecruitingNCT07697443Phase 1/2

  Sponsor listed in the registry: Chia Tai Tianqing Pharmaceutical Group Co., Ltd. · Chia Tai Tianqing Pharmaceutical Group Co., Ltd. — acquired company within the Sino Biopharmaceutical Limited group

• A LM-302 Combination With Other Anti-Tumor Therapies Phase ll StudyRecruitingNCT05934331Phase 2

  Sponsor listed in the registry: LaNova Medicines Zhejiang Co., Ltd. · LaNova Medicines Zhejiang Co., Ltd. — acquired company within the Sino Biopharmaceutical Limited group

• A Phase 2a Study of Kylo-0603 Capsule in Participants With Metabolic Dysfunction Associated Steatotic Liver Disease (MASLD)Not yet recruitingNCT07878091Phase 2

  Sponsor listed in the registry: Shanghai Chia Tai Tianqing Pharmaceutical Technology Development Co., Ltd.

• A Clinical Trial of TQF3250 Capsules in Overweight/Obese Trial Participants With Poor Weight Control Through Simple Lifestyle InterventionRecruitingNCT07798284Phase 1

  Sponsor listed in the registry: Chia Tai Tianqing Pharmaceutical Group Co., Ltd. · Chia Tai Tianqing Pharmaceutical Group Co., Ltd. — acquired company within the Sino Biopharmaceutical Limited group

• A Phase I/II of LM-364 as a Single Agent or in Combination With Anti-tumor Therapy in Patients With Advanced Solid TumorsNot yet recruitingNCT07847905Phase 1/2

  Sponsor listed in the registry: LaNova Medicines Limited · LaNova Medicines Limited — acquired company within the Sino Biopharmaceutical Limited group

• Clinical Trial of TQA3605 Tablet in Combination With Nucleos(t)Ide Analogues(NAs) Versus NAs Alone for the Treatment of Patients With Chronic Hepatitis B Virus Infection Who Have Undergone Treatment and Exhibit Low Viral Load or Poor ResponseNot yet recruitingNCT07797231Phase 3

  Sponsor listed in the registry: Chia Tai Tianqing Pharmaceutical Group Co., Ltd. · Chia Tai Tianqing Pharmaceutical Group Co., Ltd. — acquired company within the Sino Biopharmaceutical Limited group

• TQB2922 Injection Given Under the Skin With Chemotherapy as Initial Treatment for Colorectal Cancer That Has SpreadNot yet recruitingNCT07844187Phase 1/2

  Sponsor listed in the registry: Shanghai Chia Tai Tianqing Pharmaceutical Technology Development Co., Ltd.

• Evaluation of the Inhaled TQC3721 Suspension in Patients With Moderate-to-Severe Chronic Obstructive Pulmonary DiseaseRecruitingNCT07464587Phase 3

  Sponsor listed in the registry: Chia Tai Tianqing Pharmaceutical Group Co., Ltd. · Chia Tai Tianqing Pharmaceutical Group Co., Ltd. — acquired company within the Sino Biopharmaceutical Limited group

• Treatment of Chinese Adult Subjects With Moderate to Severe Crohn's Disease With Tabellvi®RecruitingNCT07663526Phase 4

  Sponsor listed in the registry: Chia Tai Tianqing Pharmaceutical Group Co., Ltd. · Chia Tai Tianqing Pharmaceutical Group Co., Ltd. — acquired company within the Sino Biopharmaceutical Limited group

• A Clinical Trial Evaluating TQB2930 Injection and Chemotherapy With or Without Bevacizumab in Patients With HER2-Abnormally Expressed Unresectable Locally Advanced or Metastatic Colorectal Cancer.RecruitingNCT07653685Phase 1/2

  Sponsor listed in the registry: Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.

• A Clinical Trial of TQB6426 for Injection in Patients With Advanced Solid TumorsRecruitingNCT07730190Phase 1

  Sponsor listed in the registry: Shanghai Chia Tai Tianqing Pharmaceutical Technology Development Co., Ltd.

• Clinical Trial Evaluating TQB6411 Injection in Participant s With Esophageal CancerRecruitingNCT07367516Phase 1/2

  Sponsor listed in the registry: Chia Tai Tianqing Pharmaceutical Group Co., Ltd. · Chia Tai Tianqing Pharmaceutical Group Co., Ltd. — acquired company within the Sino Biopharmaceutical Limited group

• Clinical Trial of TQB2922 Injection (Subcutaneous Injection) in Patients With Advanced CancersRecruitingNCT07260708Phase 1

  Sponsor listed in the registry: Shanghai Chia Tai Tianqing Pharmaceutical Technology Development Co., Ltd.

• A Clinical Trial of Taibowei® Adalimumab Injection in the Treatment of Chinese Pediatric Patients With Moderately to Severely Active Crohn's DiseaseRecruitingNCT07564505Phase 4

  Sponsor listed in the registry: Chia Tai Tianqing Pharmaceutical Group Co., Ltd. · Chia Tai Tianqing Pharmaceutical Group Co., Ltd. — acquired company within the Sino Biopharmaceutical Limited group

• A Clinical Trial of TQH3906 Capsules in Adult Patients With Moderate to Severe Plaque PsoriasisRecruitingNCT07724366Phase 3

  Sponsor listed in the registry: Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.

• A Clinical Trial on the Efficacy and Safety of TQB6411 for InjectionRecruitingNCT07367529Phase 1/2

  Sponsor listed in the registry: Chia Tai Tianqing Pharmaceutical Group Co., Ltd. · Chia Tai Tianqing Pharmaceutical Group Co., Ltd. — acquired company within the Sino Biopharmaceutical Limited group

• Study on the Safety and Efficacy of Polymyxin E2 Methanesulfonate for Injection in the Treatment of Hospital-Acquired Bacterial Pneumonia/Ventilator-Associated Bacterial Pneumonia Caused by Carbapenem-Resistant Gram-Negative BacteriaRecruitingNCT07512596Phase 2

  Sponsor listed in the registry: Chia Tai Tianqing Pharmaceutical Group Co., Ltd. · Chia Tai Tianqing Pharmaceutical Group Co., Ltd. — acquired company within the Sino Biopharmaceutical Limited group

• A Clinical Trial of TQH3906 Capsules in the Treatment of Active Psoriatic ArthritisRecruitingNCT07406035Phase 2

  Sponsor listed in the registry: Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.

• A Clinical Trial of TQF6422 Injection in Overweight or Obese Healthy Subjects.Not yet recruitingNCT07794111Phase 1

  Sponsor listed in the registry: Shanghai Chia Tai Tianqing Pharmaceutical Technology Development Co., Ltd.

• A Phase I/II Study of LM-2417 in Subjects With Advanced Solid TumoursRecruitingNCT06682780Phase 1/2

  Sponsor listed in the registry: LaNova Medicines Limited · LaNova Medicines Limited — acquired company within the Sino Biopharmaceutical Limited group

• A Clinical Trial Evaluating TQF3250 Capsules in Patients With Type 2 Diabetes Mellitus and Overweight/ObesityRecruitingNCT07747857Phase 1

  Sponsor listed in the registry: Chia Tai Tianqing Pharmaceutical Group Co., Ltd. · Chia Tai Tianqing Pharmaceutical Group Co., Ltd. — acquired company within the Sino Biopharmaceutical Limited group

• A Clinical Trial of TQ05105 Tablets in the Treatment of Chronic Graft-versus-host DiseaseRecruitingNCT06300320Phase 2

  Sponsor listed in the registry: Chia Tai Tianqing Pharmaceutical Group Co., Ltd. · Chia Tai Tianqing Pharmaceutical Group Co., Ltd. — acquired company within the Sino Biopharmaceutical Limited group

• TQC2731 Clinical Trial for the Treatment of Severe Asthma With InjectionRecruitingNCT06829784Phase 3

  Sponsor listed in the registry: Shanghai Chia Tai Tianqing Pharmaceutical Technology Development Co., Ltd.

• A Clinical Trial on the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of TQB3019 Capsule in Subjects With Advanced Malignant TumorsRecruitingNCT06943677Phase 1

  Sponsor listed in the registry: Chia Tai Tianqing Pharmaceutical Group Co., Ltd. · Chia Tai Tianqing Pharmaceutical Group Co., Ltd. — acquired company within the Sino Biopharmaceutical Limited group

• A Clinical Trial to Evaluate the Efficacy and Safety of TQB3909 Tablets Versus Investigator's Choice in the Treatment of Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL)Not yet recruitingNCT07753369Phase 3

  Sponsor listed in the registry: Chia Tai Tianqing Pharmaceutical Group Co., Ltd. · Chia Tai Tianqing Pharmaceutical Group Co., Ltd. — acquired company within the Sino Biopharmaceutical Limited group

• Clinical Trial Evaluating the Efficacy and Safety of TQB3454 Tablets in Participants With Advanced Solid TumorsNot yet recruitingNCT07738679Phase 2

  Sponsor listed in the registry: Chia Tai Tianqing Pharmaceutical Group Co., Ltd. · Chia Tai Tianqing Pharmaceutical Group Co., Ltd. — acquired company within the Sino Biopharmaceutical Limited group

• A Study of LM-168 Combined With Other Anti-tumor Treatments in Participants With Advanced Solid TumorsRecruitingNCT07669415Phase 2

  Sponsor listed in the registry: LaNova Medicines Limited · LaNova Medicines Limited — acquired company within the Sino Biopharmaceutical Limited group

• A Clinical Study of TQB3107 Tablets in Patients With Malignant TumorsRecruitingNCT06413953Phase 1

  Sponsor listed in the registry: Chia Tai Tianqing Pharmaceutical Group Co., Ltd. · Chia Tai Tianqing Pharmaceutical Group Co., Ltd. — acquired company within the Sino Biopharmaceutical Limited group

• A Multicenter, Open-label Study on the Efficacy and Safety of Tebiovio® (Adalimumab) in Treating Chinese Children With Severe Plaque PsoriasisRecruitingNCT07663331Phase 4

  Sponsor listed in the registry: Chia Tai Tianqing Pharmaceutical Group Co., Ltd. · Chia Tai Tianqing Pharmaceutical Group Co., Ltd. — acquired company within the Sino Biopharmaceutical Limited group

• A Clinical Trial to Evaluate the Efficacy, Safety, and Pharmacokinetics of TQ05105 Tablets in Subjects With Intermediate/High-risk MyelofibrosisRecruitingNCT07551427Phase 2

  Sponsor listed in the registry: Chia Tai Tianqing Pharmaceutical Group Co., Ltd. · Chia Tai Tianqing Pharmaceutical Group Co., Ltd. — acquired company within the Sino Biopharmaceutical Limited group

• A Study of LM-364 as a Single Agent or in Combination With Anti-tumor Therapy in Patients With Advanced Solid TumorsNot yet recruitingNCT07694765Phase 1/2

  Sponsor listed in the registry: LaNova Medicines Limited · LaNova Medicines Limited — acquired company within the Sino Biopharmaceutical Limited group

• A Clinical Trial on the Efficacy and Safety of TQH3906 in the Treatment of Systemic Lupus ErythematosusRecruitingNCT07509892Phase 2

  Sponsor listed in the registry: Chia Tai Tianqing Pharmaceutical Group Co., Ltd. · Chia Tai Tianqing Pharmaceutical Group Co., Ltd. — acquired company within the Sino Biopharmaceutical Limited group

• Clinical Study on the Efficacy and Safety of LM-302 Injection Combined With Tislelizumab and Tislelizumab Combined Chemotherapy for the Treatment of Gastric or Gastroesophageal Junction Adenocarcinoma.RecruitingNCT07385703Phase 3

  Sponsor listed in the registry: Shanghai Chia Tai Tianqing Pharmaceutical Technology Development Co., Ltd.

• To Evaluate the Tolerability and Pharmacokinetics of TQB3142 for Injection in Patients With Advanced Malignant TumorsRecruitingNCT07338838Phase 1

  Sponsor listed in the registry: Chia Tai Tianqing Pharmaceutical Group Co., Ltd. · Chia Tai Tianqing Pharmaceutical Group Co., Ltd. — acquired company within the Sino Biopharmaceutical Limited group

• Clinical Studies of TQB2930 Injection for the Treatment of Advanced Solid TumorsRecruitingNCT07512583Phase 1/2

  Sponsor listed in the registry: Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.

• TQB2930 Injection for the Treatment of HER2-positive Advanced Breast CancerRecruitingNCT07047365Phase 3

  Sponsor listed in the registry: Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.

• Clinical Trial Comparing TQB2868 Injection Combined With Anlotinib Hydrochloride Capsules With Placebo Combined With Chemotherapy as First-line Treatment for Metastatic Pancreatic Ductal Adenocarcinoma (mPDAC)RecruitingNCT07165951Phase 3

  Sponsor listed in the registry: Shanghai Chia Tai Tianqing Pharmaceutical Technology Development Co., Ltd.

• Evaluation of TQ-B3234 Capsules in Patients With Symptomatic, Non-Surgical Type 1 Neurofibromatosis-Associated Plexiform NeurofibromasRecruitingNCT07407803Phase 3

  Sponsor listed in the registry: Chia Tai Tianqing Pharmaceutical Group Co., Ltd. · Chia Tai Tianqing Pharmaceutical Group Co., Ltd. — acquired company within the Sino Biopharmaceutical Limited group

• Treatment of Recurrent/Metastatic Head and Neck CancerNot yet recruitingNCT07601204Phase 1/2

  Sponsor listed in the registry: Shanghai Chia Tai Tianqing Pharmaceutical Technology Development Co., Ltd.

• Clinical Trial of TQH3906 Capsules for the Treatment of Adult Patients With Moderately to Severely Active Ulcerative Colitis or Crohn's DiseaseRecruitingNCT06754891Phase 1

  Sponsor listed in the registry: Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.

• LM-108 in Combination With Toripalimab Versus Paclitaxel Injection for the Treatment of Subjects With CCR8-Positive Gastric and Gastroesophageal Junction AdenocarcinomaRecruitingNCT07362186Phase 3

  Sponsor listed in the registry: LaNova Medicines Limited · LaNova Medicines Limited — acquired company within the Sino Biopharmaceutical Limited group

• Clinical Study of TQB2934 Injection in Relapsed/Refractory Multiple MyelomaNot yet recruitingNCT07569757Phase 3

  Sponsor listed in the registry: Chia Tai Tianqing Pharmaceutical Group Co., Ltd. · Chia Tai Tianqing Pharmaceutical Group Co., Ltd. — acquired company within the Sino Biopharmaceutical Limited group

• Assessment of the Efficacy and Safety of Injectable TQB2934 (Subcutaneous Injection) in Systemic Light Chain Amyloidosis PatientsRecruitingNCT07266116Phase 1/2

  Sponsor listed in the registry: Shanghai Chia Tai Tianqing Pharmaceutical Technology Development Co., Ltd.

• Clinical Trials of Benmelstobart Injection Combined With Anlotinib Hydrochloride Capsules in the Treatment of Advanced or Unresectable Alveolar Soft Part SarcomaRecruitingNCT07548177Phase 2

  Sponsor listed in the registry: Chia Tai Tianqing Pharmaceutical Group Co., Ltd. · Chia Tai Tianqing Pharmaceutical Group Co., Ltd. — acquired company within the Sino Biopharmaceutical Limited group

• Efficacy and Safety of TRD205 Tablets for Postoperative Analgesia in Unilateral Total Hip Arthroplasty (Phase IIb)RecruitingNCT07543796Phase 2

  Sponsor listed in the registry: Beijing Tide Pharmaceutical Co., Ltd · Beijing Tide Pharmaceutical Co., Ltd — acquired company within the Sino Biopharmaceutical Limited group

• A Clinical Study to Evaluate the Pharmacokinetics and Safety of Anecatibin Fumarate Capsules in Subjects With Impaired Liver Function Versus Normal Liver FunctionNot yet recruitingNCT07538973Phase 1

  Sponsor listed in the registry: Chia Tai Tianqing Pharmaceutical Group Co., Ltd. · Chia Tai Tianqing Pharmaceutical Group Co., Ltd. — acquired company within the Sino Biopharmaceutical Limited group

• Clinical Trial of TQB3205 Capsule in Subjects With Advanced Malignant TumorsRecruitingNCT07482592Phase 1

  Sponsor listed in the registry: Chia Tai Tianqing Pharmaceutical Group Co., Ltd. · Chia Tai Tianqing Pharmaceutical Group Co., Ltd. — acquired company within the Sino Biopharmaceutical Limited group

• A Clinical Trail of Adalimumab in Treating Chinese Children With Severe Plaque PsoriasisNot yet recruitingNCT07529925Phase 4

  Sponsor listed in the registry: Chia Tai Tianqing Pharmaceutical Group Co., Ltd. · Chia Tai Tianqing Pharmaceutical Group Co., Ltd. — acquired company within the Sino Biopharmaceutical Limited group

• A Study of TQB2102 for Injection in the Treatment of HER2-positive Biliary Tract CancerRecruitingNCT06431490Phase 1/2

  Sponsor listed in the registry: Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.

• To Evaluate the Pharmacokinetics and Safety of TQ05105 Tablet in Hepatic Impairment SubjectsRecruitingNCT07480824Phase 1

  Sponsor listed in the registry: Chia Tai Tianqing Pharmaceutical Group Co., Ltd. · Chia Tai Tianqing Pharmaceutical Group Co., Ltd. — acquired company within the Sino Biopharmaceutical Limited group